ZYMEWORKS INC (US)(ZYME)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZYME ZYMEWORKS INC (US)

交易中 02-26 13:51:27 EST

23.48

-0.64

-2.65%

最高24.03	最低22.94	成交量19.75万
今开24.03	昨收24.12	日振幅4.52%
总市值17.57亿	流通市值8.99亿	总股本7,484万
成交额459.25万	换手率0.52%	流通股本3,830万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZYME","market":"US","secType":"STK","nameCN":"ZYMEWORKS INC (US)","latestPrice":23.48,"timestamp":1772131885932,"preClose":24.12,"halted":0,"volume":197524,"delay":0,"changeRate":-0.026533996683250436,"floatShares":38299500,"shares":74836534,"eps":-0.84316,"marketStatus":"交易中","change":-0.64,"latestTime":"02-26 13:51:27 EST","open":24.03,"high":24.03,"low":22.94,"amount":4592516.3551280005,"amplitude":0.045191,"askPrice":23.5,"askSize":8,"bidPrice":23.43,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.84316,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772139600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1493352000000,"exchange":"NASDAQ","adjPreClose":24.12,"preHourTrading":{"tag":"盘前","latestPrice":24.04,"preClose":24.12,"latestTime":"09:29 EST","volume":101,"amount":2427.920113,"timestamp":1772116199999,"change":-0.08,"changeRate":-0.003317,"amplitude":0.004975},"postHourTrading":{"tag":"盘后","latestPrice":24.71,"preClose":24.12,"latestTime":"17:47 EST","volume":19751,"amount":479141.93,"timestamp":1772059663257,"change":0.59,"changeRate":0.024461,"amplitude":0.024876},"volumeRatio":0.571039,"impliedVol":0.5257,"impliedVolPercentile":0.3028},"requestUrl":"/m/hq/s/ZYME","defaultTab":"news","newsList":[{"id":"1173499227","title":"财报前瞻｜ZYMEWORKS INC (US)本季度营收预计下降69.96%，关注合作收入波动","url":"https://stock-news.laohu8.com/highlight/detail?id=1173499227","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173499227?lang=zh_cn&edition=full","pubTime":"2026-02-23 10:47","pubTimestamp":1771814861,"startTime":"0","endTime":"0","summary":"ZYMEWORKS INC 将于2026年03月02日美股盘前发布最新季度财报，市场聚焦合作收入节奏与亏损幅度的变化。公司目前主营构成中，研究与发展合作收入贡献度最高，上季度该项收入2,761.40万美元，带动公司营收同比增长72.59%，显示合作回款与里程碑兑现对收入形成显著拉动。在收入构成高度集中的背景下，本季度营收一致预期为1,357.63万美元，同比下降69.96%，意味着市场对大额里程碑或预付款确认的可见度偏低。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"财报前瞻｜ZYMEWORKS INC (US)本季度营收预计下降69.96%，关注合作收入波动","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME"],"gpt_icon":0},{"id":"1190548313","title":"Zymeworks宣布管理层任命与战略转型 以配合企业战略演进","url":"https://stock-news.laohu8.com/highlight/detail?id=1190548313","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190548313?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:01","pubTimestamp":1768215705,"startTime":"0","endTime":"0","summary":"Zymeworks今日公布多项高管人事调整，此次变动旨在配合公司战略方向的持续演进。通过优化领导团队结构，公司将更聚焦于核心业务发展，强化在生物制药领域的创新布局。此次人事调整涉及关键岗位的任命与职责交接，预计将为下一阶段的技术突破与商业化进程提供组织保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"1198643606","title":"Zymeworks公司：ZW191治疗实体瘤的全球一期临床试验持续进行，卵巢癌剂量优化研究同步展开","url":"https://stock-news.laohu8.com/highlight/detail?id=1198643606","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198643606?lang=zh_cn&edition=full","pubTime":"2026-01-12 07:02","pubTimestamp":1768172563,"startTime":"0","endTime":"0","summary":"Zymeworks Inc宣布，其创新药物ZW191针对实体瘤治疗的全球一期临床试验目前正按计划持续推进。该试验的一个重要组成部分——针对卵巢癌患者的ZW191剂量优化研究——也已同步展开。\n此次临床试验旨在评估ZW191在多种实体瘤中的安全性和初步疗效，同时通过卵巢癌患者的剂量探索，为后续研究确定最佳给药方案。这一双轨并进的策略彰显了公司加速肿瘤疗法开发的决心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"1124776669","title":"Zymeworks有望获得最高4.4亿美元监管里程碑款项 涉及Ziihera在美欧日中四地上市审批","url":"https://stock-news.laohu8.com/highlight/detail?id=1124776669","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124776669?lang=zh_cn&edition=full","pubTime":"2026-01-12 07:01","pubTimestamp":1768172473,"startTime":"0","endTime":"0","summary":"生物技术公司Zymeworks Inc宣布，其创新药物Ziihera若能在美国、欧洲、日本及中国四大关键市场成功获得监管批准，公司将有望触发总计最高达4.4亿美元的里程碑付款。这一潜在收益凸显了Ziihera的全球商业化价值，也反映出国际监管机构对该疗法前景的认可。随着Ziihera在主要医药市场的审批进程推进，这些阶段性付款将为企业研发管线注入持续动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2593484934","title":"Zymeworks Inc.盘中异动 临近午盘急速下跌5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593484934","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593484934?lang=zh_cn&edition=full","pubTime":"2025-12-24 00:32","pubTimestamp":1766507547,"startTime":"0","endTime":"0","summary":"北京时间2025年12月24日00时32分，Zymeworks Inc.股票出现波动，股价快速跳水5.39%。截至发稿，该股报26.13美元/股，成交量14.3743万股，换手率0.19%，振幅4.16%。Zymeworks Inc.股票所在的生物技术行业中，整体跌幅为0.25%。Zymeworks Inc.公司简介：Zymeworks Inc 是一家临床阶段的生物制药公司，致力于下一代多功能生物治疗药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122400322797a09c47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025122400322797a09c47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"1110103207","title":"Zymeworks宣布战略举措，通过建立多元化的收入资产组合来优化授权产品的价值","url":"https://stock-news.laohu8.com/highlight/detail?id=1110103207","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110103207?lang=zh_cn&edition=full","pubTime":"2025-11-18 14:00","pubTimestamp":1763445613,"startTime":"0","endTime":"0","summary":"Zymeworks宣布战略举措，通过建立多元化的收入资产组合来优化授权产品的价值","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"1138002361","title":"Zymeworks宣布癌症药物Ziihera临床试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1138002361","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138002361?lang=zh_cn&edition=full","pubTime":"2025-11-17 22:45","pubTimestamp":1763390738,"startTime":"0","endTime":"0","summary":"11月17日，Zymeworks盘前一度涨超50%！此前公布了癌症药物Ziihera的试验结果。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"12b9cc00d05cc390c8f725385f7a4061","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Zymeworks宣布癌症药物Ziihera临床试验取得积极结果","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME"],"gpt_icon":0},{"id":"1184657518","title":"因癌症药物在晚期试验中达到主要目标，Jazz Pharma盘前飙逾30%，Zymeworks盘前升幅扩大至60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184657518","media":"老虎资讯综合","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184657518?lang=zh_cn&edition=full","pubTime":"2025-11-17 19:54","pubTimestamp":1763380474,"startTime":"0","endTime":"0","summary":"生物医药公司 Jazz Pharmaceuticals（JAZZ）盘前飙逾30%，至 185美元；公司表示，其药物 Ziihera 联合化疗用于治疗一种胃癌的晚期研究中，已达到主要研究目标。根据 JAZZ 的说法，Ziihera 在试验中相比标准治疗联合化疗，在无进展生存期（PFS）和总体生存期（OS）方面均展现出显著且具有统计学意义的改善JAZZ 与  $ZYMEWORKS INC (US)(ZYME)$ （ZYME）共同拥有该疗法的权益；ZYME 盘前股价也上涨近60%。公司计划在 2026 年上半年向美国 FDA 提交该适应症的上市申请、Ziihera 已在美国获批用于治疗一种胆道癌。","market":"us","thumbnail":"https://static.tigerbbs.com/d17cb0ea313437e7afb8bad7f25dce9a","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/d17cb0ea313437e7afb8bad7f25dce9a"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"12b9cc00d05cc390c8f725385f7a4061","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"因癌症药物在晚期试验中达到主要目标，Jazz Pharma盘前飙逾30%，Zymeworks盘前升幅扩大至60%","news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","JAZZ"],"gpt_icon":0},{"id":"1190301852","title":"ZYMEWORKS INC：基于Herizon-Gea-01三期结果，Jazz将在2026年上半年提交补充生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1190301852","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190301852?lang=zh_cn&edition=full","pubTime":"2025-11-17 19:02","pubTimestamp":1763377361,"startTime":"0","endTime":"0","summary":"ZYMEWORKS INC：基于Herizon-Gea-01三期结果，Jazz将在2026年上半年提交补充生物制品许可申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"12b9cc00d05cc390c8f725385f7a4061","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","BK4139"],"gpt_icon":0},{"id":"1199339398","title":"Zymeworks: Ziihera联合化疗在无进展生存期方面相比曲妥珠单抗联合化疗表现出临床显著且统计学意义重大的改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1199339398","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199339398?lang=zh_cn&edition=full","pubTime":"2025-11-17 19:01","pubTimestamp":1763377302,"startTime":"0","endTime":"0","summary":"Zymeworks: Ziihera联合化疗在无进展生存期方面相比曲妥珠单抗联合化疗表现出临床显著且统计学意义重大的改善","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"12b9cc00d05cc390c8f725385f7a4061","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"1167970260","title":"ZYMEWORKS发布ZW191抗体药物偶联物的I期临床试验初步数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1167970260","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167970260?lang=zh_cn&edition=full","pubTime":"2025-10-24 00:31","pubTimestamp":1761237069,"startTime":"0","endTime":"0","summary":"ZYMEWORKS发布ZW191抗体药物偶联物的I期临床试验初步数据，ZW191靶向叶酸受体-⍺，数据在AACR-NCI-EORTC会议上公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"1141024038","title":"Zymeworks Inc计划在2026年上半年为其Dll3靶向三特异性T细胞结合器ZW209提交IND申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1141024038","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141024038?lang=zh_cn&edition=full","pubTime":"2025-09-02 18:01","pubTimestamp":1756807308,"startTime":"0","endTime":"0","summary":"Zymeworks Inc正在为ZW209准备IND申请文件，该产品是公司开发的Dll3靶向三特异性T细胞结合器，计划于2026年上半年提交申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"1180404395","title":"Zymeworks宣布终止ZW171临床开发项目，该药物为间皮素靶向T细胞接合器","url":"https://stock-news.laohu8.com/highlight/detail?id=1180404395","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180404395?lang=zh_cn&edition=full","pubTime":"2025-09-02 18:00","pubTimestamp":1756807216,"startTime":"0","endTime":"0","summary":"Zymeworks公司日前宣布，决定停止其ZW171药物的临床开发工作。据悉，ZW171是一款靶向间皮素的T细胞接合器药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2518351746","title":"Zymeworks(ZYME.US)获LifeSci Capital首次覆盖，给予优于大市评级, 目标价30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518351746","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518351746?lang=zh_cn&edition=full","pubTime":"2025-03-11 20:41","pubTimestamp":1741696878,"startTime":"0","endTime":"0","summary":"Zymeworks(ZYME.US)获LifeSci Capital首次覆盖，给予优于大市评级, 目标价30.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11204148668017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ZYME"],"gpt_icon":0},{"id":"2518208789","title":"HC Wainwright & Co.：维持Zymeworks(ZYME.US)评级，由中性调整至中性评级, 目标价由12.00美元调整至13.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518208789","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518208789?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:11","pubTimestamp":1741626683,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：维持Zymeworks(ZYME.US)评级，由中性调整至中性评级, 目标价由12.00美元调整至13.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11011148641372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ZYME"],"gpt_icon":0},{"id":"2518278212","title":"Zymeworks Inc.盘中异动 快速跳水5.08%报11.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278212","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518278212?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:10","pubTimestamp":1741615859,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时10分，Zymeworks Inc.股票出现异动，股价急速下跌5.08%。截至发稿，该股报11.39美元/股，成交量12.567万股，换手率0.18%，振幅3.50%。Zymeworks Inc.股票所在的生物技术行业中，整体涨幅为0.08%。Zymeworks Inc.公司简介：Zymeworks Inc 是一家临床阶段的生物制药公司，致力于下一代多功能生物治疗药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022105996403fe5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022105996403fe5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"2518228484","title":"Zymeworks Inc.2024财年实现净利润-1.23亿美元，同比减少3.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518228484","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518228484?lang=zh_cn&edition=full","pubTime":"2025-03-10 00:00","pubTimestamp":1741536055,"startTime":"0","endTime":"0","summary":"3月10日，Zymeworks Inc.公布财报，公告显示公司2024财年净利润为-1.23亿美元，同比减少3.36%；其中营业收入为76.30百万美元，同比增加0.38%，每股基本收益为-1.62美元。从资产负债表来看，Zymeworks Inc.总负债1.24亿美元，其中短期债务2.74百万美元，资产负债比为3.74，流动比率为0.04。机构评级：截至2025年3月10日，当前有7家机构对Zymeworks Inc.目标价做出预测，其中目标均价为20.71美元，其中最低目标价为12.00美元，最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000120a268981f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000120a268981f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZYME"],"gpt_icon":0},{"id":"2517246181","title":"花旗：维持Zymeworks(ZYME.US)评级，由买入调整至买入评级, 目标价由18.00美元调整至19.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517246181","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517246181?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:13","pubTimestamp":1741385596,"startTime":"0","endTime":"0","summary":"花旗：维持Zymeworks(ZYME.US)评级，由买入调整至买入评级, 目标价由18.00美元调整至19.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08061348605306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ZYME"],"gpt_icon":0},{"id":"2517169322","title":"Zymeworks Inc.盘中异动 早盘股价大跌7.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517169322","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517169322?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:32","pubTimestamp":1741271543,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时32分，Zymeworks Inc.股票出现异动，股价大幅下挫7.02%。截至发稿，该股报12.26美元/股，成交量1.7717万股，换手率0.03%，振幅2.81%。Zymeworks Inc.股票所在的生物技术行业中，整体跌幅为0.66%。Zymeworks Inc.公司简介：Zymeworks Inc 是一家临床阶段的生物制药公司，致力于下一代多功能生物治疗药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223223a2628ff8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223223a2628ff8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZYME"],"gpt_icon":0},{"id":"1114803733","title":"异动解读 | ZYMEWORKS INC盘后大跌5.46%,业绩未达预期令市场失望","url":"https://stock-news.laohu8.com/highlight/detail?id=1114803733","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114803733?lang=zh_cn&edition=full","pubTime":"2025-03-06 05:42","pubTimestamp":1741210976,"startTime":"0","endTime":"0","summary":"ZYMEWORKS INC(ZYME.US)在周三盘后交易中股价大跌5.46%,引发了市场的广泛关注。\n\n根据公司最新季度财报,ZYMEWORKS INC当季每股亏损0.31美元,远高于分析师共识预期的0.03美元亏损。公司营收为3103万美元,也未达到分析师预期的4520万美元水平。\n\n业绩未达预期使得投资者对ZYMEWORKS INC未来增长前景感到失望,导致了公司股价在盘后交易中出现大幅下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | ZYMEWORKS INC盘后大跌5.46%,业绩未达预期令市场失望","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZYME"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zymeworks.com","stockEarnings":[{"period":"1week","weight":0.0528},{"period":"1month","weight":0.0528},{"period":"3month","weight":-0.1175},{"period":"6month","weight":0.6286},{"period":"1year","weight":0.7775},{"period":"ytd","weight":-0.0839}],"compareEarnings":[{"period":"1week","weight":0.01},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0198},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.0165}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Zymeworks Inc.于2022年6月根据特拉华州法律注册成立。Zymeworks是一家临床阶段的生物制药公司，开发多样化的新型多功能生物治疗药物管道，以提高难以治疗的疾病的护理标准。Zymeworks的治疗平台套件及其完全集成的药物开发引擎能够对高度差异化的候选产品进行精确工程设计。Zymeworks的主要临床候选药物zanidatamab是一种新型Azymetric HER2靶向双特异性抗体，目前正在全球多个1期、2期和关键临床试验中进行评估，作为表达HER2的实体瘤患者的靶向治疗选择。Zymeworks的第二个临床候选药物Zanidatamab Zovodotin（ZW49）是一种新型双特异性HER2靶向抗体药物偶联物，目前处于1期临床开发阶段，将Zanidatamab的独特设计和抗体框架与Zymeworks专有的ZymeLink 接头和细胞毒素相结合。Zymeworks还在肿瘤学（包括免疫肿瘤药物）和其他治疗领域推进深入的临床前管道。此外，通过与全球生物制药公司的战略合作伙伴关系，正在利用其治疗平台3。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.015488},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.052777},{"month":3,"riseRate":0.375,"avgChangeRate":-0.032876},{"month":4,"riseRate":0.625,"avgChangeRate":0.039222},{"month":5,"riseRate":0.333333,"avgChangeRate":0.017913},{"month":6,"riseRate":0.555556,"avgChangeRate":-0.046141},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.030946},{"month":8,"riseRate":0.888889,"avgChangeRate":0.104131},{"month":9,"riseRate":0.444444,"avgChangeRate":0.038592},{"month":10,"riseRate":0.666667,"avgChangeRate":0.043198},{"month":11,"riseRate":0.777778,"avgChangeRate":0.135367},{"month":12,"riseRate":0.555556,"avgChangeRate":0.004939}],"exchange":"NASDAQ","name":"ZYMEWORKS INC (US)","nameEN":"ZYMEWORKS INC (US)"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ZYMEWORKS INC (US)(ZYME)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ZYMEWORKS INC (US)(ZYME)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ZYMEWORKS INC (US),ZYME,ZYMEWORKS INC (US)股票,ZYMEWORKS INC (US)股票老虎,ZYMEWORKS INC (US)股票老虎国际,ZYMEWORKS INC (US)行情,ZYMEWORKS INC (US)股票行情,ZYMEWORKS INC (US)股价,ZYMEWORKS INC (US)股市,ZYMEWORKS INC (US)股票价格,ZYMEWORKS INC (US)股票交易,ZYMEWORKS INC (US)股票购买,ZYMEWORKS INC (US)股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ZYMEWORKS INC (US)(ZYME)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ZYMEWORKS INC (US)(ZYME)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}